兰卫医学
(301060)
| 流通市值：38.32亿 | | | 总市值：42.62亿 |
| 流通股本：3.60亿 | | | 总股本：4.01亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 287,160,602 | 1,448,033,298.51 | 1,102,095,711.13 | 759,388,284.42 |
| 营业收入 | 287,160,602 | 1,448,033,298.51 | 1,102,095,711.13 | 759,388,284.42 |
| 二、营业总成本 | 271,327,012.7 | 1,426,919,718.5 | 1,065,770,911.06 | 737,940,752 |
| 营业成本 | 208,683,324.21 | 1,101,049,071.38 | 835,515,526.13 | 588,178,035.39 |
| 税金及附加 | 1,307,435.64 | 5,752,910.5 | 4,083,362.65 | 2,852,029.49 |
| 销售费用 | 15,257,405.56 | 84,708,443.2 | 59,573,189.24 | 38,854,498.53 |
| 管理费用 | 36,826,056.34 | 193,682,514.22 | 126,048,137.93 | 81,307,833.46 |
| 研发费用 | 8,419,788.78 | 41,052,866.06 | 38,357,166.74 | 24,609,239.63 |
| 财务费用 | 833,002.17 | 673,913.14 | 2,193,528.37 | 2,139,115.5 |
| 其中:利息费用 | 1,046,355.5 | 6,414,337.38 | 4,839,102.3 | 3,585,277.82 |
| 其中:利息收入 | 224,757.95 | 6,116,680.71 | 2,994,059.79 | 1,733,989.57 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 0 | 51,715.73 | 51,715.73 | 51,715.73 |
| 加:投资收益 | 1,655,667.24 | 6,442,536.71 | -767,864.78 | -1,822,039.79 |
| 净敞口套期收益 | 0 | - | - | - |
| 资产处置收益 | -85,100.26 | -1,265,461.17 | -500,711.14 | -31,469.29 |
| 资产减值损失(新) | -1,356,045.89 | -15,453,256.09 | -3,236,727.51 | -6,495,306.77 |
| 信用减值损失(新) | 25,422,129.9 | -3,749,827.32 | -13,501,833.7 | -12,174,034.53 |
| 其他收益 | 4,761,004.11 | 7,772,455.56 | 6,600,265.04 | 4,585,302.9 |
| 四、营业利润 | 46,231,244.4 | 14,911,743.43 | 24,969,643.71 | 5,561,700.67 |
| 加:营业外收入 | 178,743.37 | 1,354,421.44 | 942,397.83 | 732,026.93 |
| 减:营业外支出 | 448,217.9 | 5,734,859.64 | 4,463,808.51 | 2,517,386.44 |
| 五、利润总额 | 45,961,769.87 | 10,531,305.23 | 21,448,233.03 | 3,776,341.16 |
| 减:所得税费用 | 7,504,761.35 | 25,953,815.54 | 11,240,980.75 | 7,583,042.18 |
| 六、净利润 | 38,457,008.52 | -15,422,510.31 | 10,207,252.28 | -3,806,701.02 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 38,457,008.52 | -15,422,510.31 | 10,207,252.28 | -3,806,701.02 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 36,913,244.73 | -30,746,454.09 | -667,742.31 | -5,783,174.11 |
| 少数股东损益 | 1,543,763.79 | 15,323,943.78 | 10,874,994.59 | 1,976,473.09 |
| 扣除非经常损益后的净利润 | 8,953,863.81 | -44,549,230.61 | -7,537,499.9 | -7,643,223.39 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | -0.08 | 0 | -0.01 |
| (二)稀释每股收益 | 0.09 | -0.08 | 0 | -0.01 |
| 九、综合收益总额 | 38,457,008.52 | -15,422,510.31 | 10,207,252.28 | -3,806,701.02 |
| 归属于母公司股东的综合收益总额 | 36,913,244.73 | -30,746,454.09 | -667,742.31 | -5,783,174.11 |
| 归属于少数股东的综合收益总额 | 1,543,763.79 | 15,323,943.78 | 10,874,994.59 | 1,976,473.09 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-28 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |